Search hospitals > Virginia > Fairfax
INOVA Fair Oaks Hospital
Claim this profileFairfax, Virginia 22033
Conducts research for Cancer
Conducts research for Breast Cancer
Conducts research for Squamous Cell Carcinoma
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Oropharyngeal Cancer
26 reported clinical trials
15 medical researchers
Summary
INOVA Fair Oaks Hospital is a medical facility located in Fairfax, Virginia. This center is recognized for care of Cancer, Breast Cancer, Squamous Cell Carcinoma, Non-Small Cell Lung Cancer, Oropharyngeal Cancer and other specialties. INOVA Fair Oaks Hospital is involved with conducting 26 clinical trials across 77 conditions. There are 15 research doctors associated with this hospital, such as Adam Cohen, MD, Raymond C Wadlow, MD, Kathleen K. Harnden, and John F. Deeken.Area of expertise
1Cancer
Stage IV
Stage I
Stage II
2Breast Cancer
HER2 positive
ER positive
ER negative
Top PIs
Adam Cohen, MDInova Schar Cancer Institute1 year of reported clinical research
Studies Glioblastoma
Studies Brain Tumor
10 reported clinical trials
21 drugs studied
Raymond C Wadlow, MDInova Schar Cancer Institute2 years of reported clinical research
Studies Pancreatic Cancer
Studies Pancreatic Cyst
8 reported clinical trials
17 drugs studied
Kathleen K. HarndenInova Schar Cancer Institute1 year of reported clinical research
Studies Breast Cancer
Studies Cancer
7 reported clinical trials
22 drugs studied
John F. DeekenInova Schar Cancer Institute2 years of reported clinical research
Studies Cancer
Studies Squamous Cell Carcinoma
6 reported clinical trials
12 drugs studied
Clinical Trials running at INOVA Fair Oaks Hospital
Breast Cancer
Gastroesophageal Junction Adenocarcinoma
Esophageal Adenocarcinoma
Esophageal Carcinoma
Non-Small Cell Lung Cancer
Prostate Cancer
Lung Cancer
Cancer
Squamous Cell Carcinoma
Rectal Cancer
Pembrolizumab
for Triple-Negative Breast Cancer
The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation will result in the same risk of cancer coming back as pembrolizumab after surgery in triple-negative breast cancer patients who achieve pathologic complete response after preoperative chemotherapy with pembrolizumab.
Recruiting2 awards Phase 319 criteria
T-DM1 + Tucatinib
for Breast Cancer
This phase III trial studies how well trastuzumab emtansine (T-DM1) and tucatinib work in preventing breast cancer from coming back (relapsing) in patients with high risk, HER2 positive breast cancer. T-DM1 is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called DM1. Trastuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors, and delivers DM1 to kill them. Tucatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving T-DM1 and tucatinib may work better in preventing breast cancer from relapsing in patients with HER2 positive breast cancer compared to T-DM1 alone.
Recruiting1 award Phase 313 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at INOVA Fair Oaks Hospital?
INOVA Fair Oaks Hospital is a medical facility located in Fairfax, Virginia. This center is recognized for care of Cancer, Breast Cancer, Squamous Cell Carcinoma, Non-Small Cell Lung Cancer, Oropharyngeal Cancer and other specialties. INOVA Fair Oaks Hospital is involved with conducting 26 clinical trials across 77 conditions. There are 15 research doctors associated with this hospital, such as Adam Cohen, MD, Raymond C Wadlow, MD, Kathleen K. Harnden, and John F. Deeken.